0001493152-20-021707.txt : 20201223 0001493152-20-021707.hdr.sgml : 20201223 20201116163512 ACCESSION NUMBER: 0001493152-20-021707 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIXTE BIOTECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001335105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202903526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 BUSINESS PHONE: 310 203 2902 MAIL ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 FORMER COMPANY: FORMER CONFORMED NAME: SRKP 7 INC DATE OF NAME CHANGE: 20050803 CORRESP 1 filename1.htm

LIXTE BIOTECHNOLGY HOLDINGS, INC.

248 Route 25A, No.2

East Setauket, NY 11733

November 16.2020

VIA EDGAR

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-6010

	Re:	Lixte Biotechnology Holdings, Inc.
		Registration Statement on Form S-1 (Reg. No. 333-248588)

Ladies and Gentlemen:

On behalf of Lixte Biotechnology Holdings, Inc., the undersigned hereby requests that the Securities and Exchange Commission issue an order declaring the above-referenced Registration Statement effective at 4:00 P.M., Washington, D.C. time, on Wednesday, November 18,2020 or as soon thereafter as is practicable. Please call our counsel, David Ficksman, at 310-789-1290 to inform him of the effectiveness.

	Very truly yours,

	/s/ John Kovach
	John Kovach
	President and Chief Executive Officer